The selective estrogen receptor modulator DT56a (Femarelle) does not affect platelet reactivity in normal or thrombophilic postmenopausal women.
Nachtigall
Margaret J
MJ
Department of Obstetrics and Gynecology, NYU Interdisciplinary Program in Menopausal Medicine, New York University School of Medicine, New York, NY 10016, USA.
Jessel
Rebecca H
RH
Flaumenhaft
Robert
R
Nachtigall
Richard
R
Yoles
Israel
I
Naftolin
Frederick
F
Nachtigall
Lila E
LE
D000328:Adult; D000368:Aged; D017153:Antibodies, Anticardiolipin / Q000097:blood; D001792:Blood Platelets / Q000187:drug effects* / Q000502:physiology*; D016022:Case-Control Studies; D000075202:Contraindications; D015914:Estrogen Replacement Therapy; D005165:Factor V / Q000235:genetics; D005260:Female; D006801:Humans; D008875:Middle Aged; D009154:Mutation; D010936:Plant Extracts / Q000009:adverse effects* / Q000627:therapeutic use*; D017698:Postmenopause / Q000097:blood / Q000502:physiology*; D018455:Protein S Deficiency; D011516:Prothrombin / Q000235:genetics; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use; D019851:Thrombophilia / Q000097:blood* / Q000209:etiology / Q000235:genetics
D017153:Antibodies, Anticardiolipin; C478341:DT56a; D010936:Plant Extracts; D020845:Selective Estrogen Receptor Modulators; C095381:factor V Leiden; D005165:Factor V; D011516:Prothrombin